7 Fortunately, during the “Decade of Vaccines,” 20 million additional children, and at least 90% coverage of the three-dose diphtheria-tetanus-pertussis vaccines in more than hundred countries were vaccinated. The vaccine industry in all countries was supposed to play a significant role in these initiatives. 6 In 2010, nearly 200 countries committed to a shared global health vision called the “Decade of Vaccine Initiative (DoV) (2010–2020).” The main aim was to achieve 90% vaccination coverage in developing countries to prevent around 7.6 million under-5 child mortality. 5 In 2008, the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property was adopted at the World Health Assembly. Some countries with relatively high per capita income are not eligible for support from Gavi, the Vaccine Alliance (GAVI) in accessing new vaccines. These nations are largely dependent on imports. 4 The primary reason behind this is the lack of equitable access to basic vaccines in the low-income and middle-income developing nations. At present, 19.5 million infants worldwide are still at risk of vaccine-preventable diseases (VPDs) because they miss out on basic vaccines. 2, 3 These numbers are projected to increase by at least 6 million if all children are vaccinated as per the recommended vaccination schedule. As per the World Health Organization (WHO), approved vaccines prevent 2 to 3 million deaths per year. 1 It has become a key to the cost-effective reduction of mortality, improvement of life expectancy, and economic growth. Prevention of diseases by vaccination is one of the most significant achievements in medical` research history. Capacity building for the manufacturing of vaccines in developing countries has always been an area of paramount importance and more so in a pandemic situation. Technology transfer has improved vaccine access and reduced prices of vaccines. There is a need for capacity building of workforce development, technology transfer, and financial support.
In a continuously evolving vaccine landscape, the need of the hour for developing nations is to manufacture their own vaccines besides having supply security, control over production scheduling and sustainability, control of costs, socio-economic development, and rapid response to local epidemics. A robust and stable manufacturing process and constant raw material supplies over decades is critical.
Challenges in the life cycle of vaccine production include process development, lead time, intellectual property, and local vaccine production. There is a lack of equitable access to vaccines in the low- and middle-income developing nations. The continued production expansion and deliverability improvement of COVID-19 vaccines have met domestic demands and supported epidemic control overseas to the best of China's ability, said Tian.įor the rest of the year, Tian said the ministry will continue to guide vaccine producers to ensure safe and stable vaccine production.Īt the same time, the ministry will coordinate domestic and overseas demands and support vaccine producers to boost international capacity cooperation, so as to make vaccines more accessible and affordable and contribute to the global pandemic fight, said Tian.Approved vaccines prevent 2 to 3 million deaths per year. The country has sent up to 570 million doses of COVID-19 vaccines overseas to aid the global fight against the COVID-19 virus, Tian Yulong, chief engineer at the MIIT, told a press conference.ĭomestically, over 1.4 billion doses of COVID-19 vaccines have been administered as the country continues to ramp up its inoculation drive, according to Tian. China's annual production capacity for COVID-19 vaccines has reached 5 billion doses as of July, said the Ministry of Industry and Information Technology (MIIT).
0 kommentar(er)
